Codiak BioSciences is a clinical-stage biopharmaceutical company focused on the development of exosome-based therapeutics. One of Co.'s clinical stage programs, exoSTING, is an exosome therapeutic candidate delivering its proprietary STING agonist while expressing high levels of Prostaglandin F2 receptor negative regulator (PTGFRN) on the exosome surface to facilitate specific uptake in tumor-resident antigen-presenting cells. Co.'s other clinical stage program, exoIL-12, displays IL-12 in an active form on the surface of the engineered exosome. Co.'s third clinical stage program, exoASO-STAT6, overexpresses PTGFRN to selectively target uptake in M2-polarized tumor-associated-macrophages. We show 10 historical shares outstanding datapoints in our coverage of CDAK's shares outstanding history.
Understanding the changing numbers of CDAK shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like CDAK versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching CDAK by allowing them to research CDAK shares outstanding history
as well as any other stock in our coverage universe. |
Free CDAK Email Alerts:
Video: Shares Outstanding Importance
